It has been widely demonstrated that in the late-onset eosinophilic phenotype, the presence of allergy does not represent a factor impacting the efficacy of the anti-eosinophilic therapeutic approach [47,48], demonstrating how this eosinophil-driven phenotype is untied to allergenic stimuli and therefore could not be effectively modulated using drugs targeting T2 inflammatory cytokines (anti IL-5 and IL-4/13) or anti-IgE. The gene discussed is IGHE; the disease is Allergy.